Group items tagged

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

The NHS England has developed and published a new vaccination strategy with an aim to increase national uptake of lifesaving vaccinations, and protect people against a range of diseases. Getting vaccinations will become easier than ever before, as the NHS App is being expanded with more additional features. Improved booking features such as new in-App bookings, invitation alerts and appointment notifications will make "booking a jab as easy as booking a cab," NHS leaders said. The NHS App overhaul will also include improved access to medical records, meaning users will be able to see their routine vaccination status over the coming months and years, making it easier for them to identify any missed vaccinations in their history.

GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.

All children aged five to 11 in England will be offered a Covid-19 vaccine, the government said on Wednesday (February 16) - following similar announcements in the rest of the UK. The move, coming nearly two months after British regulators approved Pfizer and BioNTech's shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries. It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective". However, health secretary Sajid Javid - who has responsibility for England only - said he had now accepted guidance from the Joint Committee on Vaccination and Immunisation, which advises UK health departments, to expand the rollout. "The NHS will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses, a new study published in The Lancet has revealed. The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and boosters by summer 2022. In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent, 34.2 per cent for Scotland and 32.8 per cent Wales. Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and older from across the four countries during June 1 to September 30 2022.

The government will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an "urgent reversal" to a fall in uptake as the country faces a worsening measles outbreak. Routine childhood immunisations in Britain for diseases including measles, mumps and rubella, diphtheria and polio, have been falling gradually over the past decade, but dipped more sharply after the Covid-19 pandemic, mirroring a global decline. Last year UNICEF said people worldwide had lost confidence in the importance of routine childhood vaccines during the pandemic, with misinformation, dwindling trust in governments and political polarisation contributing to rising hesitancy. Britons will begin seeing adverts from next week across various media, including a television campaign featuring children reminding parents of the risk of missing out on vaccinations, the UK Health Security Agency (UKHSA) said. "We need an urgent reversal of the decline in the uptake of childhood vaccinations to protect our communities," UKHSA chief executive Jenny Harries said in a statement.

The flu vaccine is recommended for all , starting with children from 6 months age by US Centers for Disease Control and Prevention (CDC). To have a greater effect than the flu vaccine is advisable to be vaccinated immediately when vaccines are available in the fall. The objective is to sufficiently during your body to build immunity against influenza virus before flu season is in height. If your child turns 6 months old, in the middle of winter , not worry . No problem to get your flu shot, even in late January or beginning of February .

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot. The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators. The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said. "To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022." No safety concerns were identified. This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022. "We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call. Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and manufacturing problems. Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.

Community pharmacies saved nearly 20,000 lives up to autumn 2021 by vaccinating people against the Covid-19, the National Pharmacy Association said based on a National Audit Office (NAO) report released on Friday (February 25). The report, having taken evidence from the NPA, highlighted that community pharmacies and GPs performed far beyond expectations in delivering the Covid-19 vaccine, as 71 per cent of jabs were administered by both healthcare providers till October-end, against an initial assumption of 56 per cent. The report cited UK Health Security Agency figures, which estimated that the programme overall prevented up to 128,000 deaths and 262,000 hospitalisations by September 24 and September 19, respectively. The estimated number is considerably higher, given the pivotal role played by pharmacies in this winter's phase of the vaccination programme, the NPA stated.

Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS) initiative, the Cancer Vaccine Launch Pad. This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country. The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS Foundation Trust. Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial. Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.

Covid-19 booster jab can now be administered sooner than six months after the second dose to certain vulnerable people as guideline in the UK Health Security Agency (UKHSA) Green Book has been updated. With the change in the guidance, care home residents who have been given their second vaccine dose at different times will be able to be jabbed in the same session, as long as it has been at least five months since their last dose. It may also help with other vulnerable groups, such as housebound patients to have their flu and Covid-19 vaccines at the same time. The move will also benefit those who are about to receive immunosuppressive treatment as they can get the booster from a minimum of four months after their second dose. Health secretary Sajid Javid said: "This updated guidance will ensure healthcare professionals have the necessary flexibility in the booster programme, allowing more vulnerable people to be vaccinated where it makes operational sense to do so." Vaccines minister Maggie Throup also encouraged eligible people to book their booster jab and secure protection.

As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19 vaccine face termination in just a fortnight. Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022. Those who are exempted from taking the vaccination do not fall under this purview. According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31. All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period

A pair of pharmacist brothers, who also own a popular restaurant in Kent, have started an innovative initiative 'Jabs with Kebabs' to encourage their community in England to come forward and take their Covid-19 vaccines. Rav and Raj Chopra, who own V's Punjabi Grill, an Indian restaurant in Gravesend, established the walk-in vaccine site after their father, Jagtar Chopra, became unwell with Covid-19 last year. The duo is among thousands to volunteer for the National Health Service (NHS) vaccine programme. Talking to the PA news agency, Raj said he was inspired by the experience of his father, who got infected with the virus and has fully recovered since then. "From a personal point of view, it was very debilitating to see Dad like that," said Raj Chopra. "It got everyone's emotions in play.

Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned on Tuesday (November 30), as countries ramp up vaccination programmes and impose further restrictions in an effort to curb growing concern. First reported to the World Health Organization in South Africa less than a week ago, the new strain has rapidly spread from Africa to the Pacific, and from Europe to North America as dozens of countries have announced travel restrictions. While no deaths have yet been reported from Omicron, and it could take weeks to know how infectious and how resistant the strain may prove to vaccines, its emergence underscores how besieged the world remains by Covid-19, nearly two years after the first cases were recorded. Stephane Bancel, the head of US vaccine manufacturer Moderna, told the Financial Times in an interview published today that data would be available on the effectiveness of vaccines in the two weeks' time, but that scientists were pessimistic.

Has the government in England learned nothing from the Covid-19 pandemic? Nigel Swift, Managing Director of Rowlands Pharmacy, part of Numark, the UK's largest pharmacy membership association, asks reflecting on the disorderly launch of this year's flu and Covid booster vaccination program as evidence to the contrary. "Community pharmacies play a crucial role in ensuring eligible individuals can easily access their free NHS flu and Covid vaccinations," Swift said, adding that delivering this essential service necessitates pharmacy staff allocating time for preparation and appointment scheduling. "Just a few weeks ago, NHSE informed us that the vaccination program would be postponed until October, prompting pharmacies to plan accordingly and notify patients," he said. "However, NHSE has now reversed its decision and set the program to commence on Sept. 11. Pharmacy recommended an earlier start, but NHSE opted for a delay instead, resulting in avoidable problems." On Aug. 30, NHSE announced plans to move up the start of the autumn vaccination drive in England to September 11, deviating from the initial October schedule, citing concerns about a new Covid-19 variant.